| Literature DB >> 30913256 |
Christine E McLaren1, Wen-Pin Chen2, Nadine A Bertalli3,4, Martin B Delatycki4,5,6, Graham G Giles3,7, Dallas R English3,7, John L Hopper3, Katrina J Allen4,5,8, Lyle C Gurrin3.
Abstract
Homozygosity for the p.C282Y substitution in the HFE protein encoded by the hemochromatosis gene on chromosome 6p (HFE) is a common genetic trait that increases susceptibility to iron overload. McLaren et al. used bivariate mixture modeling to analyze the joint population distribution of transferrin saturation (TS) and serum ferritin concentration (SF) measured for participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. They identified four components (C1, C2, C3, and C4) with successively increasing means for TS and SF. They demonstrated that bivariate mixture modeling in TS and SF reflect the genetic locus of HFE and may isolate p.C282Y homozygotes from the general population. In the current study we used data from the another large cohort, the Australian HealthIron study of genetic and environmental modifiers of hereditary hemochromatosis, to validate the component analysis approach, to examine stability of component proportions over time and to determine if TS and SF values from an individual move between components at baseline and follow-up. Because sampling fractions from each p.C282Y / p.H63D genotype stratum are not equal, we used frequency weights based on the inverse of the probability of selection for invitation to participate. In the weighted female analytic cohorts, C4 captured most of C282Y homozygotes, and C2 was the largest component. We identified four components from the weighted male analytic cohort and C4 captured most of p.C282Y homozygotes. The bivariate mixture modeling approach suggested that the model is transferable from one white population to another, although estimated means within components may differ.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30913256 PMCID: PMC6435128 DOI: 10.1371/journal.pone.0214196
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Exclusions for data from participants in the HealthIron study.
| Unweighted | Weighted | |||||||
|---|---|---|---|---|---|---|---|---|
| Exclusion | Women | Women | Men | Men | Women | Women | Men | Men |
| Total Sample | 783 | 783 | 655 | 655 | 16484 | 16484 | 13363 | 13363 |
| Excluded for | ||||||||
| Not in Baseline Analysis Cohort | - | 283 | - | 229 | - | 3417 | - | 3102 |
| Missing values for TS | 255 | 57 | 205 | 60 | 3331 | 1222 | 2931 | 919 |
| Missing values for SF | 2 | 1 | 3 | 1 | 60 | 3 | 150 | 50 |
| Undetermined | 26 | 0 | 18 | 0 | 26 | 0 | 18 | 0 |
| Reported previous treated for iron overload | 0 | 12 | 3 | 23 | 0 | 12 | 3 | 27 |
| Age less than 25 or unknown | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 50 |
| Final Analytic Sample | 500 | 430 | 426 | 341 | 13067 | 11830 | 10261 | 9215 |
Participants’ characteristics in the unweighted and weighted analytic samples.
| Unweighted | Weighted | |||||||
|---|---|---|---|---|---|---|---|---|
| Women | Women | Men | Men | Women | Women | Men | Men | |
| Number of participants | 500 | 430 | 426 | 341 | 13067 | 11830 | 10261 | 9215 |
| Age-yr, mean (sd) | 53.8 (9.1) | 65.2 (9.3) | 54.3 (9.1) | 65.9 (9.1) | 53.9 (9.3) | 65.5 (9.5) | 53.9 (9.2) | 65.7 (9.2) |
| Serum Ferritin (ug/L), median range | 83.5 | 112.5 | 234.0 | 187.0 | 77.0 | 97.0 | 186.0 | 162.0 |
| Transferrin Saturation (%), mean (sd) | 32.3 (16.1) | 32.1 (14.9) | 39.8 (19.1) | 35.9 (16.9) | 26.3 (9.6) | 25.9 (9.6) | 31.7 (11.0) | 30.7 (11.3) |
| Clinical assessment at baseline | ||||||||
| Self-report diabetes, % | 1 (5/500) | - | 3 (12/426) | - | 1 (163/13067) | - | 3 (328/10261) | - |
| Self-report angina, % | 2 (9/500) | - | 6 (24/426) | - | 1 (178/13067) | - | 6 (569/10261) | - |
| Self-report heart attack or myocardial infarction, % | 1 (6/500) | - | 5 (21/426) | - | 1 (108/13067) | - | 5 (491/10261) | - |
| Clinical assessment at follow-up | ||||||||
| Self-report liver disease, % | - | 8 (34/419) | - | 3 (11/335) | - | 7 (787/11561) | - | 4 (369/9042) |
| Self-report fatigue, % | - | 18 (74/421) | - | 10 (32/334) | - | 18 (2081/11614) | - | 11 (1029/9081) |
| Abnormal 2nd and 3rd MCP joints on either hand, % | - | 12 (41/354) | - | 16 (48/295) | - | 11 (1048/9785) | - | 17 (1325/8027) |
| Liver enlargement, % | - | 1 (5/342) | - | 4 (11/289) | - | 2 (154/9359) | - | 4 (287/7901) |
| Genotype | ||||||||
| HO (C282Y homozygote) | 72 | 49 | 60 | 26 | 72 | 49 | 60 | 26 |
| HEHE (C282Y/H63D compound heterozygote) | 75 | 67 | 77 | 63 | 225 | 201 | 231 | 189 |
| HEN (C282Y heterozygote) | 122 | 103 | 112 | 90 | 1220 | 1030 | 1120 | 900 |
| NHE (H63D heterozygote) | 63 | 55 | 38 | 35 | 3150 | 2750 | 1900 | 1750 |
| NHO (H63D homozygote) | 8 | 8 | 6 | 6 | 400 | 400 | 300 | 300 |
| NN (HFE wildtype) | 160 | 148 | 133 | 121 | 8000 | 7400 | 6650 | 6050 |
Note: ‘-‘ represents ‘not applicable’.
The estimated proportions and the means and variances for adjusted TS and adjusted SF within components of the bivariate distribution in the weighted analytic cohort by sex.
| Cohort | Mixture component | Estimate of mixing proportion | Estimated adjusted mean TS (%) | Estimated adjusted TS variance | Estimated adjusted mean SF (ug/L) | Estimated adjusted mean SF (ug/L) in original scale | Estimated adjusted SF variance |
|---|---|---|---|---|---|---|---|
| Women at Baseline N = 13,067 | C4 | 0.003 | 77.060 | 43.834 | 5.344 | 209.369 | 0.592 |
| C3 | 0.057 | 46.735 | 43.834 | 4.993 | 147.304 | 0.592 | |
| C2 | 0.821 | 28.351 | 43.834 | 4.338 | 76.524 | 0.592 | |
| C1 | 0.118 | 16.299 | 43.834 | 2.638 | 13.984 | 0.592 | |
| Women at Follow-up N = 11,830 | C4 | 0.009 | 61.187 | 36.233 | 5.049 | 155.804 | 0.724 |
| C3 | 0.288 | 35.218 | 36.233 | 5.185 | 178.573 | 0.724 | |
| C2 | 0.627 | 23.479 | 36.233 | 4.351 | 77.587 | 0.724 | |
| C1 | 0.076 | 12.083 | 36.233 | 2.384 | 10.853 | 0.724 | |
| Men at Baseline N = 10,261 | C4 | 0.010 | 77.955 | 56.098 | 5.671 | 290.441 | 0.477 |
| C3 | 0.160 | 47.121 | 56.098 | 5.513 | 247.819 | 0.477 | |
| C2 | 0.686 | 31.046 | 56.098 | 5.454 | 233.668 | 0.477 | |
| C1 | 0.145 | 24.993 | 56.098 | 3.831 | 46.104 | 0.477 | |
| Men at Follow-up N = 9,215 | C4 | 0.068 | 55.619 | 62.295 | 5.472 | 237.959 | 0.547 |
| C3 | 0.638 | 32.073 | 62.295 | 5.522 | 250.135 | 0.547 | |
| C2 | 0.234 | 26.722 | 62.295 | 3.953 | 52.097 | 0.547 | |
| C1 | 0.060 | 14.619 | 62.295 | 2.503 | 12.219 | 0.547 |
1Estimated adjusted SF in original scale = exp(Ln(SF))
Fig 1Scatter plots of adjusted TS and SF with indication of the C282Y homozygote cases as red dots from HealthIron study.
The 95% confidence ellipses in black and in green were based on the 4-component models from HealthIron and HEIRS data, respectively. The weighted analytic cohorts: A. Female at baseline, B. Female at follow-up, C. Male at baseline and D. Male at follow-up.
The contingency table of baseline versus follow-up group membership among females (N = 11830).
| 1 | 150 | 736 | 283 | 6 | 1175 |
| 2 | 490 | 6823 | 2724 | 35 | 10072 |
| 3 | 60 | 165 | 295 | 45 | 565 |
| 4 | 0 | 2 | 9 | 7 | 18 |
| Total | 700 | 7726 | 3311 | 93 | 11830 |
The contingency table of baseline versus follow-up group membership among males (N = 9215).
| 1 | 273 | 399 | 380 | 101 | 1153 |
| 2 | 236 | 1416 | 4964 | 244 | 6860 |
| 3 | 50 | 146 | 775 | 161 | 1132 |
| 4 | 0 | 51 | 1 | 18 | 70 |
| Total | 559 | 2012 | 6120 | 524 | 9215 |